Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 37,811 |
|
|||||
| News | - | ||||||
| Day High | 4.77 | Low High |
|||||
| Day Low | 4.53 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Annexon Inc | ANNX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.04 | -0.87% | 4.55 | 09:36:26 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.65 | 4.53 | 4.77 | 4.59 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 149 | 37,811 | $ 4.65 | $ 175,701 | - | 1.57 - 8.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 09:36:26 | 100 | $ 4.55 | USD |
Annexon Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 244.37M | 53.24M | - | 0 | -134.24M | -2.52 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Annexon News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ANNX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.33 | 4.85 | 4.26 | 4.51 | 1,731,366 | 0.22 | 5.08% |
| 1 Month | 7.10 | 7.31 | 4.26 | 5.49 | 1,549,477 | -2.55 | -35.92% |
| 3 Months | 4.17 | 8.40 | 3.86 | 5.89 | 1,728,722 | 0.38 | 9.11% |
| 6 Months | 1.93 | 8.40 | 1.90 | 5.15 | 1,258,873 | 2.62 | 135.75% |
| 1 Year | 5.53 | 8.40 | 1.57 | 4.43 | 967,660 | -0.98 | -17.72% |
| 3 Years | 21.28 | 24.85 | 1.57 | 5.84 | 542,888 | -16.73 | -78.62% |
| 5 Years | 16.8635 | 38.01 | 1.57 | 7.31 | 468,528 | -12.31 | -73.02% |
Annexon Description
| Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases. |
